A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Apr 2018 Planned primary completion date changed from 22 Oct 2019 to 14 Nov 2020.
- 28 Feb 2018 Planned End Date changed from 4 Sep 2020 to 14 Nov 2020.
- 31 Jan 2018 Planned End Date changed from 12 Aug 2020 to 4 Sep 2020.